


## LY2955303

<b>Cat. No.:</b>	HY-107765		
<b>CAS No.:</b>	1433497-19-8		
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>42</sub> N <sub>4</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	578.74		
<b>Target:</b>	RAR/RXR; Autophagy		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 30 mg/mL (51.84 mM; Need ultrasonic and warming)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	1.7279 mL	8.6395 mL	17.2789 mL
	<b>5 mM</b>	0.3456 mL	1.7279 mL	3.4558 mL
	<b>10 mM</b>	0.1728 mL	0.8639 mL	1.7279 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2 mg/mL (3.46 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (3.46 mM); Clear solution			

### BIOLOGICAL ACTIVITY

<b>Description</b>	LY2955303 is a potent and selective retinoic acid receptor gamma (RAR $\gamma$ ) antagonist with a K <sub>i</sub> of 1.09 nM.
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 1.09 nM (RAR $\gamma$ ) <sup>[1]</sup>
<b>In Vitro</b>	LY2955303 is tested and observed that the binding K <sub>i</sub> s for RAR $\alpha$ , RAR $\beta$ and RAR $\gamma$ are >1700, >2980 and 1.09 nM, respectively. The functional K <sub>i</sub> for RAR $\gamma$ is 7.1±4.9 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	A single oral dose of LY2955303 demonstrates a dose responsive effect whereby the rat reduces differential weight bearing (ED <sub>50</sub> =0.72 mg/kg) <sup>[1]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cell Res. 2022 Jun;32(6):513-529.
- Mediators Inflamm. 2022 Nov 7;2022:1875736.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Hughes NE, et al. Identification of potent and selective retinoic acid receptor gamma (RAR $\gamma$ ) antagonists for the treatment of osteoarthritis pain using structure based drug design. Bioorg Med Chem Lett. 2016 Jul 15;26(14):3274-3277.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA